

DAFTAR PUSTAKA

- Abiageli Uzoamaka Agbogu-ike, Ogoina D, Geoffrey C. 2021. Leptin Concentrations in Non-Obese and Obese Non-Diabetes Nigerian-Africans. *Diabetes Metab Syndr Obes.* 2021; 14: 4889–4902. PMC 8710913. doi: 10.2147/DMSO.S264735
- Aldibbiat, M.A., Ahmed A. 2020. Do Benefits Outweigh Risks for Corticosteroid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in People with Diabetes Mellitus?. *International journal of Chronic Obstructive Pulmonary Disease* 2020; 15: 567–574. doi: 10.2147/COPD.S236305
- Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. 2009. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. *J Am Coll Cardiol.* 2009 Apr 28;54(8):669-77. DOI: 10.1016/j.jacc.2009.03.076.
- Ataey A, J. E.-A. (n.d.). 2020. The Relationship Between Obesity, Overweight, and the Human Development Index in World Health Organization Eastern Mediterranean Region Countries. *J Prev Med Public Health (2020)* 53(2):98–105. doi:10.3961/jpmph.19.100
- Barale, C., Melchionda E, Tempesta G, Morotti A, Russo I. 2023. Impact of Physical Exercise on Platelets: Focus on Its Effects in Metabolic Chronic Diseases. *Antioxidants.* 2023; 12(8):1609. <https://doi.org/10.3390/antiox12081609>
- Barazzoni, R., G. G. 2018. Insulin resistance in obesity: an overview of fundamental alterations. *Studies on Anorexia, Bulimia and Obesity (2018)* 23:149–157. doi:<https://doi.org/10.1007/s40519-018-0481-6>
- Bereket A, Zeynep A. 2012. Current status of childhood obesity and its associated morbidities in Turkey. *J Clin Res Pediatr Endocrinol* 2012;4(1):1-7.
- Bulbul Ahmad, R. S. 2021. Adipose tissue and insulin resistance in obese. *Biomedicine & Pharmacotherapy* 137 (2021) 111315. doi:<https://doi.org/10.1016/j.biopha.2021.111315>
- Cahyaningrum. 2015. Leptin sebagai indikator obesitas, Sandubaya Mataram. *Jurnal Kesehatan Prima, I(1), 1364–1371.*
- Calabro P., Cirillo P., Limongelli G., Maddalono V., Riegler R., Palmieri R., Pacileo G., De rosa S., Pacileo M., Angri V, et al. 2009. Tissue Factor is induced by resistin in human coronary artery endothelial cells by the NF-kappaB-dependent Pathway. *J Vasc Res.* 2009;46(5):423-31. Doi: 10.1159/000182747.

- Cerezo, J., Jose, E., Pardo, J. 2022. Update on new forms of Tobacco use actualization of new ways of consuming Tobacco. *Clinical Investigation an arteriosclerosis*. Vol 34, Issues 6, November-December 2022, Pages 330-338. Doi: <https://doi.org/10.1016/j.artere.2022.10.005>
- Chaurasia, B. & Summers, S. A. Ceramides in metabolism: key lipotoxic players. 2021. *Annu. Rev. Physiol.* 83, 303–330 (2021).
- Chen, X., Qingyao, W., Chong, X., Shuyi, J., Shuxian. 2022. sCD40L Is Increased and Associated with the Risk of Gestational Diabetes Mellitus in Pregnant Women with Isolated TPOAb Positivity. *Int J Endocrinol* 2022 Aug 13;2022:2946891. doi:10.1155/2022/2946891
- Chooi, C. D. 2018. The epidemiology of obesity. *Metabolism Journal*, September 2018, S0026-0495(18)30194-X, 4-7. doi:10.1016/j.metabol.2018.09.005
- Corica D, A. T. (n.d.). 2018. Does Family History of Obesity, Cardiovascular, and Metabolic Diseases Influence Onset and Severity of Childhood Obesity. *Front Endocrinol (Lausanne)* (2018) 9:187. doi:10.3389/fendo.2018.00187
- Dallak, M., Bin-Jaliah, I., Sakr, H.F., Al-Ani, B., Haidara, M.A. 2019. Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance. *Arch. Physiol. Biochem.* 2019, 125, 79–84.
- Decroli, E., Rudy, A., Kam, A., Puspita, U. 2022. Correlation between Insulin Resistance with Soluble CD40 Ligand and Plasminogen Activator Inhibitor-1 Plasma in Pre-diabetic Patients. *Macedonian Journal of Medical Sciences.* 2022 Februari 15; 10(B):351-356. doi:<https://doi.org/10.3889/oamjs.2022.8202>
- Elgueta R, B. M. 2013. Molecular mechanism and function of CD40/CD40L engagement in the immune system. *Immunol Rev.* 2013 Mei; 229(1):. doi:10.1111/j.1600-065X.2009.00782.x
- Ferroni, P., Fiorella, G. 2008. Soluble CD40L and its role in essential Hypertension: Diagnostic and Therapeutic implications. *Cardiovasc Hematol Disord Drug Targets.* 2008 Sep;8(3):194-202. Doi: 10.2174/187152908785849125
- Fisher-Wellman, K. H. & Neuffer, P. D. 2012. Linking mitochondrial bioenergetics to insulin resistance via redox biology. *Trends Endocrinol. Metab.* 23, 142–153 (2012). An excellent review of the role of mitochondrial bioenergetics and ROS in Insulin Resistance.
- Fuentes, E., Ivan, P. 2014. Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation PPAR agonists: New antiplatelet agents. *Fascular Pharmacology.* <http://dx.doi.org/10.1016/j.vph.2014.05.008>.

- Gateva, A., Yavor, A., Tsakova, A., Kamenov, Z. 2016. Soluble CD40L is associated with insulin resistance, but not with glucose tolerance in obese nondiabetic patients. *Archives Of Physiology And Biochemistry*. doi:10.3109/13813455.2016.1160934
- Gawaz, M., et al. 2011. Platelets in inflammation: role of platelet-derived adhesion molecules in atherogenesis. *Herz*, 26(5), 235-239.
- Guldiken, S., Muzaffer, D., Arikan, E., Burhan, T., Azcan S., Murat, G., Tugryul, A. 2016. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. doi: 10.1016/j.thromres.2005.12.019.
- Han, S., Kwang, K.K., Quon, M.J., Yonghee, L., Shin, E.K. V et al. 2010. The Effects of Simvastatin, Losartan, and combined therapy on Soluble CD40 Ligand in Hypercholesterolemic, Hypertensive patients. *Atherosclerosis*. 2010 Jan;190(1):205-11. Doi: 10.1016/j.atherosclerosis.2010.01.021
- Henn, V et al. 2011. *CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells*. *Nature*, 391(6667), 591-594.
- Hilberg, T., Ransmann, P., Hagedorn, T. 2021. Sport and Venous Thromboembolism—Site, Accompanying Features, Symptoms, and Diagnosis. *Dtsch. Arztebl. Int.* 2021, 118, 181–187. [Google Scholar] [CrossRef] [PubMed]
- Huang, J., Caroline, J., Talaie, T., Austin, A., Jales, A., Kwong, Y.T., Madan, R.A., James, L.G., Schlom, J. 2012. Elevated serum Soluble CD40 Ligand in Cancer Patients may play an Immunosuppressive Role. *Journal of the American Society of Hematology*. 2012 Oct 11; 120(15): 3030–3038. doi: 10.1182/blood-2012-05-427799
- James E.D., Jacqueline S., Birnbaum M.J. 2021. The aetiology and molecular landscape of insulin resistance. *Nature Reviews | Molecular Cell Biology*. 2021 Nov;22(11):751-771. doi: 10.1038/s41580-021-00390-6.
- Jura, M., Kozak. 2016. Obesity and related consequences to ageing. August 2015. doi:https://doi.org/10.1007/s11357-016-9884-3
- Kemenkes. 2019. *Profil Kesehatan Indonesia Tahun 2019*. Jakarta: Kementerian Kesehatan RI.
- Kit Inset Horiba ABX Pentra.
- Kurniawan, L.B. 2016. The Role of Platelets sCD40L To Atherogenesis. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. Department of Clinical Pathology, Faculty of Medicine, Hasanuddin

- University/Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia. 2016 July; 22(3): 284–288. p-ISSN 0854-4263 | e-ISSN 4277-4685
- Kumar, V. A. 2018. Robbins Basic Pathology, Philadelphia, Elsevier.
- Liang, Y., Chengrui, Z., Sun, Y., Zhiliang, L., Wang, L., Yina, L., Li, X., and Xiaochun, M. 2021. Persistently higher serum sCD40L levels are associated with outcome in septic patients. Department of Critical Care Medicine, The First Hospital of China Medical University, Province, China. *BMC Anesthesiology* (2021) 21:26 <https://doi.org/10.1186/s12871-021-01241-9>
- Lin, X. L. 2021. Obesity: Epidemiology, Pathophysiology, and Therapeutics. (A. U. Claire Joanne Stocker, Ed.) *Department of Endocrinology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Endocrinol. 2021 (September) 12:706978., 1-4. doi:10.3389/fendo.2021.706978*
- Linna H, Suija K, Rajala U, Herzig KH, Karhu T, Jokelainen J. 2016. The association between impaired glucose tolerance and soluble CD40 ligand: A 15-year prospective cohort study. *Aging Clin Exp Res.* 2016;28(6):1243-9. <https://doi.org/10.1007/s40520-015-0524-z> PMID:26749117
- Luciardi, M. C., Carizzo. T., Diaz, E.I., Aleman, M.N., Bazan, M.C., Abregu, A. 2018. Proinflammatory state in obese children. *Rev Chil Pediatr.* 2018;89(3):346-351. doi:10.4067/S0370-41062018005000501
- Michel NA, Z. A. (n.d.). 2017. CD40L and its receptors in atherothrombosis-an update, *front. Cardiovascular Medical.* 2017;4:1-18. doi:<https://doi.org/10.3389/fcvm.2017.00040> PMID: 28676852.
- MyBioSource. 2023. Human Soluble Cluster of Differentiation 40 Ligand (sCD40L) ELISA Kit.
- Nadkarni, P. & Weinstock. 2017. Carbohydrates. In: Mcpherson, R. A. & Pincus, M. R. (eds.) *Henry's Clinical Diagnosis and Management by Laboratory Methods.* 23rd ed. Missouri: Elsevier.
- Nurpalah, R., S, D. N., & Holis, N. 2017. Pemeriksaan Glukosa Darah Pada Wanita Pengguna Kontrasepsi Oral Dan Pada Wanita Hamil Trimester III. *Jurnal Kesehatan Bakti Tunas Husada*, 1-5.
- Paleva, R. 2019. Mekanisme Resistensi Insulin Terkait Obesitas. *Jurnal Ilmiah Kesehatan Sandi Husada, Vol 10, No, 2, Desember 2019, pp; 354-358 . doi:10.35816/jiskh.v10i2.190*
- Park, S.Y., Jean.-F., Chon, G. 2021. Assessment of Insulin Secretion and Insulin Resistance in Human. *Diabetes Metab Journal.* 2021;45(5):641-654. doi:<https://doi.org/10.4093/dmj.2021.0220>

- Rahma, S., Mursyidah, A & Yuli, Y.R. 2019. Kadar Glukosa Darah Pengguna Kontrasepsi Hormonal. *Fakultas Olahraga dan Kesehatan Universitas Negeri Gorontalo* . JNJ Vol. 1, No. 2, juli 2019. pISSN: 2654-2927, eISSN: 2656-4653.
- Ravussin, E. & Smith. 2016. Role of the Adipocyte in Metabolism and Endocrine Function. *Endocrinology: Adult And Pediatric. 7th ed. Philadelphia: Elsevier.*
- Riskesdas. 2013. *Riset Kesehatan Dasar. Badan Penelitian Dan Pengembangan Kesehatan. Jakarta: Kementerian Kesehatan RI.*
- Riyahi.N, Eusni, R.,Thambiah, S., Zuriati, I. 2018. Platelet-related cytokines among normal body mass index, overweight, and obese Malaysians. *Asia Pacific Journal Clinical Nutrition* 2018;27(1):182-188. doi:10.6133/apjcn.032017.01
- Roche. 2013. Insulin. Indianapolis: Roche Diagnostics.
- Sacks, D. B. 2018. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Missouri: Elsevier.*
- Sameh Sarray., Wassim. Y. 2016. Levels of CD40L and other inflammatory biomarkers in obese and non-obese women with polycystic ovary syndrome. *Department of Medical Biochemistry, Arabian Gulf University, Manama, Bahrain.* doi:10.1111/aji.12549
- Sangwung, P., Petersen, K. F., Shulman, G. I. & Knowles, J. W. 2020. Mitochondrial dysfunction, insulin resistance, and potential genetic implications. *Endocrinology* 161, bqaa017.
- Santilli F, S. P. 2019. The Role of Platelets in Diabetes. *Department of Medicine and Aging and Haemostasis and Thrombosis Unit. Amsterdam, Netherlands: Elsevier; 2019, p. 469-503.*
- Santosa, B. 2020. *Buku Teknik Elisa* . Penerbit Unimus Press © 2020 Unimus Press Jl. Kedungmundu Raya No. 18 Semarang, 50273 Telp. (024) 76740296. Hal 6-7. ISBN :978-602-561493-4.
- Senchenkova, E. Y., Russell, J., Vital, S. A., Yildirim, A., Orr, A. W., Granger, D. N., Gavins, F. N. E. 2018. A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation. *Faseb Journal*. 2018 Jun;32(6):3448-3456. Doi: 10.1096/fj.201701068R
- Singh, B. & Saxena. 2010. Surrogate Markers of Insulin Resistance: A Review. *World J Diabetes*, 1, 36-47.

- Sumiyati, Y. 2012. Korelasi Antara Inflamasi dengan Aktivasi Trombosit dan Fibrinolisis pada Subyek Hipertensi dan Obesitas Sentral. Repository Universitas Hasanuddin. <http://repository.unhas.ac.id>
- Scholz, H., Sandberg, M., Rajasalu, T. et al. 2012. The angiotensin converting enzyme inhibitor enalapril and tissue angiotensin II. *Am J Hypertens* 15, 42S–47S (2012). [DOI: 10.1016/S0895-7061(01)02276-9]
- Steffen D., Lutgens E., Thomas M., Daiber A. 2020. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease – The Pros and Cons for Cardioprotection. *Int J Mol Sci.* 2020 Nov;21(22):8533. Doi: 10.3390/ijms21228533
- Tang, Q., Xueqing, P., Lingzhong, X. (n.d.). 2015. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. *Drug Discoveries & Therapeutics.* 2015; 9(6):380-385. doi:10.5582/ddt.2015.01207
- Tchernof, A. & Depress, P. 2013. Pathophysiology of Human Visceral Obesity : an update. *Physiol Rev*, 93 359–404.
- Trivigno, S.M.G., Gianni, F.G., Barbieri, S.S., Marta, Z. 2023. Bloods Platelets in Infection: The Multiple Roles of the Platelet Signalling Machinery. *International Journal of Molecular Sciences.* Vol 24(8), 7462; <https://doi.org/10.3390/ijms24087462>
- Unek, I.T., M., Firat Bayraktar, M., Dilek Solmaz, M., Hulya Ellidokuz, M., Ali Riza Sisman, M., Yuksel, F., & Sena Yesil, M. 2010. The Levels of Soluble CD40 Ligand and C-Reactive Protein in Normal Weight, Overweight and Obese People. *Clinical Medicine & Research Volume 8, Number 2: 89-95.* doi:10.3121/cmr.2010.889
- Utami, N. A. 2017. Hubungan antara pola makan dan aktivitas fisik terhadap kejadian Overweight dan Obesitas pada remaja. *Internal Medicine Journal. Diponegoro University.*
- Varo N, et al. 2013. *Soluble CD40L: risk prediction after acute coronary syndromes.* *Circulation*, 108(9), 1049-1052.
- WHO. 2014. Body mass index (BMI) is associated with morbidity and mortality from various diseases & asian cut off value. Issue Step 2, pp. 3–4. World Health Organization.

LAMPIRAN

LAMPIRAN

Lampiran 1. Surat Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpCK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 858/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 13 Nopember 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23090699		No Sponsor	
Peneliti Utama	Nur Ismi, S.Tr.Kes		Sponsor	
Judul Peneliti	Analisis Hubungan Soluble CD40 Ligand dengan Homeostasis Model Assessment Insulin Resistance Pada Subjek Obesitas Non Diabetes Melitus			
No Versi Protokol	2	Tanggal Versi	9 Nopember 2023	
No Versi PSP	2	Tanggal Versi	9 Nopember 2023	
Tempat Penelitian	RS Universitas Hasanuddin Makassar			
Jenis Review	<input type="checkbox"/> Exempted	Masa Berlaku 13 Nopember 2023 sampai 13 Nopember 2024	Frekuensi review lanjutan	
	<input checked="" type="checkbox"/> Expedited			
	<input type="checkbox"/> Fullboard Tanggal			
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan		
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Surat Pengantar Penelitian

 HUM-RC <small>HASANUDDIN UNIVERSITY MEDICAL RESEARCH CENTER science for a better future</small>	ADMINISTRASI	FORMULIR 1
	Nomor : 491/11/FR1/2023	Tanggal : 8 November 2023
SURAT PENGANTAR PENELITIAN		

Kepada Yth.

Pembimbing/pendamping,

Bapak Muhammad Yusuf Usman,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama : Nur Ismi

NIM : P062221012

Institusi : S2 Ilmu Biomedik Sekolah Pascasarjana UNHAS

Akan melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal : 9 November 2023 s/d Selesai

Jumlah subjek : ± 62 sampel

Jenis data : Data Primer

Untuk penelitian dengan judul :

“Analisis Hubungan Soluble CD40 Ligand dengan Homeostasis Model Assessment Insulin Resistance Pada Subjek Obesitas Non Diabetes Melitus”

Harap dilakukan pembimbingan dan pendampingan seperlunya. Terima Kasih.

Staf Administrasi


HUM-RC
science for a better future
Andi Fidyah Septiani

Catatan : Proses pengerjaan dilakukan oleh peneliti, Pendamping hanya mendampingi.

Jika pengambilan data telah selesai, **diwajibkan bagi pendamping/pembimbing;**

1. Membubuhi **paraf dan tanggal selesai** pengambilan data di formulir ini,
2. Mengisi **jumlah alat dan bahan habis pakai** yang digunakan peneliti pada form tarif penggunaan alat dan bahan,
3. **Mengembalikan formulir** yang sudah lengkap ke staf administrasi.

Lampiran 3. Surat Selesai Penelitian

	ADMINISTRASI	FORMULIR 2
	Nomor : 511/11/FR2/2023	Tanggal : 22 November 2023
SURAT KETERANGAN SELESAI PENGAMBILAN DATA/ ANALISA BAHAN HAYATI		

Dengan hormat,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama : Nur Ismi
NIM : P062221012
Institusi : S2 Ilmu Biomedik Sekolah PascaSarjana UNHAS
Judul Penelitian : **Analisis Hubungan Soluble CD40 Ligand dengan Homeostasis Model Assessment Insulin Resistance Pada Subjek Obesitas Non Diabetes Melitus**

Telah selesai melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal : 21 November 2023
Jumlah subjek : ± 62 sampel
Jenis data : Data Primer


Dengan staf pendamping/pembimbing :

Nama : Muhammad Yusuf Usman, S.Si.
Konsultan : -

Surat keterangan ini juga merupakan penjelasan bahwa peneliti/mahasiswa diatas tidak mempunyai sangkutan lagi pada unit/laboratorium kami.

Demikian surat ini dibuat untuk dipergunakan sebagaimana mestinya.

Pendamping/Pembimbing



Muhammad Yusuf Usman, S.Si
NIP

Mengetahui,
Kepala Laboratorium,



HUM-RC
science for a better future
dr. Rusdina Bte Ladju, Ph.D
NIP 198108302012122002



Lampiran 4. Data Primer

No Sampel	Jenis Kelamin	Umur	Berat Badan (Kg)	Tinggi Badan (cm)	IMT (Kg/M ²)	Lingkar Pinggang (cm)	HOMA-IR	sCD40L
2	P	28	51,2	150	27,2	88	1,2499	1,2709
5	P	31	63,8	158	25,6	91	2,6513	1,5568
7	L	30	67	163,5	25,1	91	3,7721	1,6872
8	P	31	66,7	156,5	27,2	99	3,9134	0,3876
12	P	29	63,7	155,5	26,3	96,5	4,2452	2,1315
24	P	30	62,9	155	26,2	90	p2,3943	1,3050
29	P	36	69,1	155	28,8	103	1,8676	2,0179
31	P	38	55,3	147	25,6	90	3,3110	1,6959
32	P	29	76,1	155	32,5	107	3,4268	1,5732
33	P	30	62,2	157	25,2	96	1,6988	1,9871
34	P	35	70,9	162	27	97	4,0184	2,0654
35	P	35	70	145	26	98	3,4614	2,3686
36	L	32	97	170	33,9	105	1,7602	2,7285
37	P	35	67,1	159	26,5	90	3,2501	2,3178
40	L	31	80	167	29	101	2,5412	2,1271
41	L	35	130,1	170	45	133	5,8736	1,6846
42	L	32	85,3	173	28,5	95	4,6497	1,7227
47	P	35	60,4	154	25,5	68,5	2,7884	2,2546
49	L	32	83,3	178	26,3	97	1,4538	2,7467
50	P	30	73,3	155	30,5	94	5,7711	2,6760
52	L	29	76,8	165	28,2	95	5,3993	1,8742
53	P	36	64,5	150	28,7	89	4,3332	2,6859
55	L	31	62,6	148	28,4	87	2,4004	1,8463
57	P	37	73,5	155	30,6	96	2,4497	2,2005
59	P	33	67,1	154	28,3	92	1,2658	2,1660
60	P	34	73,6	149	33,2	95	3,7490	1,9328
61	L	28	82,5	169,5	28,7	96,7	3,5988	2,0266
64	L	34	81,3	164	30,2	61	3,1191	1,9231
65	P	37	72,8	157	29,5	93	2,1383	1,8524
66	P	33	89,9	163	33,6	95,5	3,1103	2,0742
67	L	30	71,6	166	26	83	1,4297	1,5499
73	P	29	56,6	155	23,6	78,5	1,3183	1,4906
74	P	32	73,2	163	27,6	97	1,8917	1,4391
75	P	31	66,9	158	26,8	98,5	4,7759	1,5318
76	L	32	73,2	165	26,9	95	4,8539	2,0266
81	L	26	72,9	170	25,2	92	1,3840	1,4537
1	P	39	50,2	153	24,9	87,5	3,8445	1,7332
3	P	27	41,5	150	18,4	68	0,5345	2,4383

4	P	30	47,2	148	21,5	74	2,1902	1,4408
6	P	34	54,3	152	23,5	80,5	2,3210	1,8925
9	P	32	53,6	148,5	24,3	87,5	1,2919	1,8864
10	P	34	52,6	155,5	21,8	80,5	3,6227	1,6863
11	P	27	53,8	152	23,3	88,5	2,6426	1,7505
14	P	28	43,3	146,5	20,2	78	1,5384	1,8724
18	L	30	70,1	168	24,8	95,5	1,7079	1,5602
25	P	30	58,3	157	23,7	89	1,8705	1,3920
26	L	28	64,1	167	23	88	2,4987	1,7106
28	P	31	49,8	153	21,3	85	3,4774	1,6146
43	L	31	62	165	22,8	81	1,5294	1,9836
44	P	27	41,2	164	15,3	69	0,9791	1,9153
45	L	35	59,7	162	22,7	84	1,9034	1,7392
46	L	35	57,1	160	22,3	82	3,0629	2,0980
48	L	38	52	154	21,9	71	1,2699	1,4280
51	L	29	47,1	155	19,6	72,5	1,5487	2,2866
54	P	34	51,5	155	21,4	85	1,0490	1,6837
62	P	30	42	152,5	18,1	72	1,7898	1,8419
63	P	31	46,2	156,5	18,9	72	1,3915	1,7011
68	P	31	52,6	150	23,4	77	1,3685	2,2377
70	P	34	56,6	155	22,3	83	3,5544	1,9310
71	L	29	59,4	159	23,5	83	1,0691	1,7071
72	P	31	45,1	155	18,3	74	1,1933	1,3895
77	L	40	59,6	158	23,9	90	1,5032	1,7175
78	L	22	55,8	162	21,3	84	3,0560	1,2310
80	L	31	78,4	178	24,7	93	3,2819	1,6249
82	L	26	56,5	163	21,3	83	1,4004	1,6405
83	L	26	62	165	22,8	90	2,1558	1,8158
84	L	32	58,5	172	19,8	77	0,8857	2,2653
85	L	20	65,3	163	24,6	89	3,7286	1,4220
86	L	23	71,2	169	24,9	88	2,4479	1,8314
88	L	33	70,4	172	23,5	101	1,5810	0,9348

Lampiran 6. Dokumentasi





Lampiran 7. Riwayat Hidup (*Curriculum Vitae*)

Nama : Nur Ismi
Tempat Tanggal Lahir : Bulukumba, 07 Mei 2000
Agama : Islam
Pekerjaan : Mahasiswa S2 Ilmu Biomedik
NIP : -
Pangkat/Golongan : -
Alamat : Jl. Bontobila XII No. 2
No. Hp : 085394094524
Email : nurismiasdar99@gmail.com

No	STRATA	INSTITUSI	TEMPAT	TAHUN LULUS
1.	SD	SD Negeri 295 BALONG	Bulukumba	2011
2.	SMP	MTs. Badan Amal Ujung Loe	Bulukumba	2014
3.	SMA	SMK Muhammadiyah Bulukumba	Bulukumba	2017
4.	S1	Poltekkes Kemenkes Makassar	Makassar	2021
5.	S2 (Sementara)	Ilmu Biomedik Pascasarjana Unhas	Makassar	2022 – Sekarang